Neumora Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(in thousands)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Gain / (Loss) | Deficit | Equity | |
| Balance as of December 31, 2023 | 158,832 | $16 | $1,172,570 | $(76) | $(703,434) | $469,076 |
| Issuance of common stock upon exercise of stock options | 1,957 | — | 7,482 | — | — | 7,482 |
| Issuance of common stock under employee stock purchase plan | 52 | — | 427 | — | — | 427 |
| Issuance of common stock through at-the-market transactions net of offering costs $0.8 million | 885 | — | 13,598 | — | — | 13,598 |
| Forfeiture of restricted stock subject to repurchase | (99) | — | — | — | — | — |
| Vesting of restricted common stock | 88 | — | — | — | — | — |
| Vesting of common stock subject to repurchase | — | — | 140 | — | — | 140 |
| Repurchase of unvested early exercised stock options | (5) | — | — | — | — | — |
| Unrealized gain on marketable debt securities | — | — | — | 138 | — | 138 |
| Stock-based compensation | — | — | 39,990 | — | — | 39,990 |
| Net loss | — | — | — | — | (243,787) | (243,787) |
| Balance as of December 31, 2024 | 161,710 | $16 | $1,234,207 | $62 | $(947,221) | $287,064 |
| Forfeiture of unvested restricted common stock | (231) | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 434 | — | 275 | — | — | 275 |
| Issuance of common stock through at-the-market transactions net of offering costs $0.4 million | 7,476 | 1 | 19,652 | — | — | 19,653 |
| Vesting of restricted stock units | 370 | — | — | — | — | — |
| Vesting of common stock subject to repurchase | — | — | 155 | — | — | 155 |
| Unrealized loss on marketable debt securities | — | — | — | (62) | — | (62) |
| Stock-based compensation | — | — | 29,876 | — | — | 29,876 |
| Issuance of common stock upon conversion of convertible debt | 4,501 | — | 3,838 | — | — | 3,838 |
| Net loss | — | — | — | — | (236,928) | (236,928) |
| Balance as of December 31, 2025 | $174,260 | 17 | $1,288,003 | $— | $(1,184,149) | $103,871 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.